JP2003526685A5 - - Google Patents

Download PDF

Info

Publication number
JP2003526685A5
JP2003526685A5 JP2001566711A JP2001566711A JP2003526685A5 JP 2003526685 A5 JP2003526685 A5 JP 2003526685A5 JP 2001566711 A JP2001566711 A JP 2001566711A JP 2001566711 A JP2001566711 A JP 2001566711A JP 2003526685 A5 JP2003526685 A5 JP 2003526685A5
Authority
JP
Japan
Prior art keywords
tumor
composition
stem cells
extracranial
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001566711A
Other languages
English (en)
Other versions
JP2003526685A (ja
JP4800544B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/008273 external-priority patent/WO2001068148A1/en
Publication of JP2003526685A publication Critical patent/JP2003526685A/ja
Publication of JP2003526685A5 publication Critical patent/JP2003526685A5/ja
Application granted granted Critical
Publication of JP4800544B2 publication Critical patent/JP4800544B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Description

【特許請求の範囲】
【請求項1】
直接的または間接的抗腫瘍作用をもつ物質を送達または発現する幹細胞であって、修飾されたまたは非修飾の多数の当該幹細胞を含む、腫瘍治療を必要とする個人における腫瘍を治療するための全身送達用の組成物
【請求項2】
前記幹細胞が神経幹細胞(NSCs)である、請求項1記載組成物
【請求項3】
前記腫瘍が、神経系腫瘍であるか、頭蓋外腫瘍からの脳または脊髄転移であるか、または非神経構造体への転移をもつ頭蓋外腫瘍である、請求項1記載組成物
【請求項4】
前記全身性送達が、血管内、CSF内、または骨内注射を用いて実施される、請求項1記載組成物
【請求項5】
前記物質が、治療的利益を付与する遺伝子である、請求項1記載組成物
【請求項6】
前記遺伝子が、シトシンデアミナーゼをコードする、請求項5記載組成物
【請求項7】
シトシンデアミナーゼを発現する神経幹細胞を含む調製物を含む、腫瘍治療を必要とする個人における腫瘍を治療するための全身送達用の組成物であって、
シトシンデアミナーゼ産生細胞が、該個人に投与された無毒の5−フルオロシトシンを有毒の5−フルオロウラシルへ変換する、組成物
【請求項8】
前記腫瘍が、神経系腫瘍、頭蓋外腫瘍からの脳または脊髄転移、または非神経構造体への転移をもつ他の頭蓋外腫瘍である、請求項7記載組成物
【請求項9】
前記全身性送達が、血管内および静脈内送達である、請求項7記載組成物
【請求項10】
医薬的に許容可能な希釈剤中に、液体窒素凍結された、または活発に増殖している幹細胞を含む医薬調製物。
【請求項11】
腫瘍の全身的治療用のキットであって、前記腫瘍に治療効果を発揮するように操作されておりそして前記腫瘍の方へ移動できる凍結幹細胞または活発に増殖している幹細胞のバイアル、前記幹細胞を懸濁させるための医薬品級溶液の容器、ならびに注射器および/またはカテーテルを含む上記キット。
JP2001566711A 2000-03-15 2001-03-15 腫瘍治療用の全身性遺伝子送達運搬体 Expired - Lifetime JP4800544B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18972000P 2000-03-15 2000-03-15
US60/189,720 2000-03-15
PCT/US2001/008273 WO2001068148A1 (en) 2000-03-15 2001-03-15 Systemic gene delivery vehicles for the treatment of tumors

Publications (3)

Publication Number Publication Date
JP2003526685A JP2003526685A (ja) 2003-09-09
JP2003526685A5 true JP2003526685A5 (ja) 2008-11-13
JP4800544B2 JP4800544B2 (ja) 2011-10-26

Family

ID=22698493

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001566711A Expired - Lifetime JP4800544B2 (ja) 2000-03-15 2001-03-15 腫瘍治療用の全身性遺伝子送達運搬体

Country Status (6)

Country Link
US (1) US7393526B2 (ja)
EP (1) EP1267944B1 (ja)
JP (1) JP4800544B2 (ja)
AU (3) AU4744201A (ja)
CA (1) CA2406664C (ja)
WO (1) WO2001068148A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129034B2 (en) * 2001-10-25 2006-10-31 Cedars-Sinai Medical Center Differentiation of whole bone marrow
US20070111959A1 (en) * 2005-11-17 2007-05-17 James Yockman Combination gene for use in inhibiting cancerous cell growth
FR2901136B1 (fr) * 2006-05-18 2010-10-01 Centre Nat Rech Scient Utilisation de cellules derivees du tissu adipeux pour la preparation d'un medicament anti-tumoral
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
US8518698B1 (en) * 2007-07-06 2013-08-27 University Of Central Florida Research Foundation, Inc. Method of promoting apoptosis of glioblastoma tumor cells
DK2328923T3 (en) 2008-09-02 2016-03-21 Cedars Sinai Medical Center CD133 epitopes
PT2427485T (pt) 2009-05-07 2017-03-13 Immunocellular Therapeutics Ltd Epitopos cd133
US9057734B2 (en) 2010-08-23 2015-06-16 President And Fellows Of Harvard College Optogenetic probes for measuring membrane potential
WO2012106281A2 (en) 2011-01-31 2012-08-09 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
US20180112006A1 (en) 2015-04-17 2018-04-26 The General Hospital Corporation Agents, systems and methods for treating cancer
CA3232099A1 (en) 2021-09-23 2023-03-30 Adam Ezra Cohen Genetically encoded voltage indicators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5358866A (en) * 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US6497872B1 (en) * 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750378A (en) * 1991-12-20 1998-05-12 Fibrogenex, Inc. Method for preparing cellular fibronectin
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US5958767A (en) * 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
JP2002526104A (ja) 1998-10-07 2002-08-20 ザ・チルドレンズ・ホスピタル・メデイカル・センター・コーポレーシヨン 脳腫瘍の治療のための移植可能な神経前駆および幹細胞
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system

Similar Documents

Publication Publication Date Title
JP2003526685A5 (ja)
Li et al. Cell‐based delivery systems: emerging carriers for immunotherapy
ES2326209T3 (es) Produccion de microesferas.
CA2406664A1 (en) Systemic delivery of neural stem cells to treat cancer
Dunn et al. The neurosurgeon as local oncologist: cellular and molecular neurosurgery in malignant glioma therapy
CN106659803A (zh) 核酸疫苗
CA2294981A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
JP2015510495A (ja) 器官または器官移植片の生存可能性または寿命を延長する方法
HK1131623A1 (en) Modulators of pharmacological agents
JP2002544234A5 (ja)
CN108265052A (zh) 一种小干扰核酸和药物组合物及其用途
Chen et al. Nanomaterials: small particles show huge possibilities for cancer immunotherapy
WO2023063242A1 (ja) IFN-γへ選択的に結合するオリゴヌクレオチドを含有する自己免疫性疾患治療薬およびそのオリゴヌクレオチド
JP2006525238A (ja) 活性炭輸液剤、その調製方法及び癌治療用薬物の調製におけるその使用
WO2006077824A1 (ja) 神経細胞再生のための医薬
Visted et al. Progress and challenges for cell encapsulation in brain tumour therapy
Chen et al. Application of programmable tetrahedral framework nucleic acid-based nanomaterials in neurological disorders: Progress and prospects
WO2007001010A1 (ja) パーキンソン病の治療のための医薬
Ma et al. Intracellular Delivery of mRNA for Cell‐Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles
Huseynov et al. NOVEL NANOMATERIALS FOR HEPATOBILIARY DISEASES TREATMENT AND FUTURE PERSPECTIVES.
JP4460220B2 (ja) オリゴヌクレオチド組成物、および細胞の分化を誘導するためのオリゴヌクレオチド組成物の使用
US20170348345A1 (en) Combination Therapy For Cancer
CN113368386A (zh) 一种结合电刺激和超声的大分子药物入脑递送系统
Liu et al. Extracellular Vesicles:“Stealth Transport Aircrafts” for Drugs
Debinski Molecular targeting with recombinant cytotoxins for the treatment of brain tumors